Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:ARTV NASDAQ:CGC NASDAQ:FDMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.62-0.7%$3.83$2.90▼$11.16$318.18M0.183.63 million shs1.55 million shsARTVArtiva Biotherapeutics$2.39-6.5%$2.75$1.47▼$17.31$58.27M2.99211,598 shs82,951 shsCGCCanopy Growth$1.41+2.6%$1.29$0.77▼$5.80$336.99M0.7611.29 million shs10.32 million shsFDMT4D Molecular Therapeutics$6.79-0.3%$5.70$2.23▼$17.41$317.09M2.85851,181 shs274,112 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%ARTVArtiva Biotherapeutics0.00%-29.36%-7.27%+26.24%-74.40%CGCCanopy Growth0.00%-6.16%+5.38%-5.52%-71.40%FDMT4D Molecular Therapeutics0.00%-6.33%-6.20%+55.84%-58.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.62-0.7%$3.83$2.90▼$11.16$318.18M0.183.63 million shs1.55 million shsARTVArtiva Biotherapeutics$2.39-6.5%$2.75$1.47▼$17.31$58.27M2.99211,598 shs82,951 shsCGCCanopy Growth$1.41+2.6%$1.29$0.77▼$5.80$336.99M0.7611.29 million shs10.32 million shsFDMT4D Molecular Therapeutics$6.79-0.3%$5.70$2.23▼$17.41$317.09M2.85851,181 shs274,112 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%ARTVArtiva Biotherapeutics0.00%-29.36%-7.27%+26.24%-74.40%CGCCanopy Growth0.00%-6.16%+5.38%-5.52%-71.40%FDMT4D Molecular Therapeutics0.00%-6.33%-6.20%+55.84%-58.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40381.33% UpsideARTVArtiva Biotherapeutics 3.00Buy$17.00612.79% UpsideCGCCanopy Growth 1.33SellN/AN/AFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40347.72% UpsideCurrent Analyst Ratings BreakdownLatest ARTV, CGC, FDMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K15,953.00N/AN/A$1.74 per share2.08ARTVArtiva Biotherapeutics$250K233.06N/AN/A$7.68 per share0.31CGCCanopy Growth$225.65M1.49N/AN/A$1.90 per share0.74FDMT4D Molecular Therapeutics$40K7,927.33N/AN/A$11.05 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)ARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)CGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)Latest ARTV, CGC, FDMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/6/2025Q2 2025ARTVArtiva Biotherapeutics-$0.84-$0.87-$0.03-$0.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44ARTVArtiva BiotherapeuticsN/A13.8413.84CGCCanopy Growth0.593.072.12FDMT4D Molecular TherapeuticsN/A8.758.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ARTVArtiva BiotherapeuticsN/ACGCCanopy Growth3.33%FDMT4D Molecular Therapeutics99.27%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%ARTVArtiva Biotherapeutics21.40%CGCCanopy Growth0.16%FDMT4D Molecular Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableARTVArtiva Biotherapeutics8124.43 million19.20 millionN/ACGCCanopy Growth3,150239.85 million239.47 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableARTV, CGC, FDMT, and ALT HeadlinesRecent News About These CompaniesCubist Systematic Strategies LLC Sells 364,659 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 14 at 3:14 AM | marketbeat.com4DMT Announces New Employment Inducement GrantsSeptember 12 at 4:05 PM | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Consensus Target Price from AnalystsSeptember 11, 2025 | americanbankingnews.com4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 9, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. $FDMT Shares Acquired by Invesco Ltd.September 8, 2025 | marketbeat.comNuveen LLC Invests $486,000 in 4D Molecular Therapeutics, Inc. $FDMTSeptember 7, 2025 | marketbeat.comBVF Inc. IL Grows Position in 4D Molecular Therapeutics, Inc. $FDMTSeptember 5, 2025 | marketbeat.comJim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec”September 5, 2025 | insidermonkey.comRedmile Group LLC Sells 199,675 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 4, 2025 | marketbeat.comWellington Management Group LLP Purchases 70,192 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 3, 2025 | marketbeat.com4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2, 2025 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss RatingsSeptember 1, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comFY2025 EPS Estimates for FDMT Decreased by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comChardan Capital Has Weak Forecast for FDMT FY2025 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Brokers Lower Earnings Estimates for FDMTAugust 16, 2025 | marketbeat.comQ3 EPS Forecast for 4D Molecular Therapeutics Cut by AnalystAugust 16, 2025 | marketbeat.com4DMT Announces New Employment Inducement GrantsAugust 15, 2025 | globenewswire.comBrokers Offer Predictions for FDMT FY2027 EarningsAugust 15, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025ARTV, CGC, FDMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$3.62 -0.03 (-0.69%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Artiva Biotherapeutics NASDAQ:ARTV$2.38 -0.17 (-6.47%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Canopy Growth NASDAQ:CGC$1.40 +0.04 (+2.55%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.4D Molecular Therapeutics NASDAQ:FDMT$6.79 -0.02 (-0.29%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
